EGF induces epithelial-mesenchymal transition through phospho-Smad2/3-Snail signaling pathway in breast cancer cells
Metrics: PDF 3070 views | HTML 4227 views | ?
Jinkyoung Kim1,*, Jienan Kong2,*, Hyeyoon Chang1, Hayeon Kim1, Aeree Kim1
1Department of Pathology, Korea University Guro Hospital, Seoul 08308, Republic of Korea
2Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
*These authors have contributed equally to this work
Aeree Kim, email: [email protected]
Keywords: epidermal growth factor (EGF), Smad2/3, EMT, breast cancer, small interfering RNA (siRNA)
Received: July 05, 2016 Accepted: October 22, 2016 Published: November 04, 2016
Epithelial-mesenchymal transition (EMT) can contribute to tumor invasion, metastasis, and resistance to chemotherapy or hormone therapy. EMT may be induced by a variety of growth factors, such as epidermal growth factor (EGF). Most studies regarding EMT have focused on TGF-β-Smads signaling. The mechanism of EGF-induced EMT via activation of the Smad2/3 in breast cancer cells, MCF-7 and MDA-MB-231, remains unclear. The expression levels of Snail, vimentin, and fibronectin were increased by EGF treatment in a time-dependent manner, while the expression level of E-cadherin was decreased. EGF-induced nuclear co-localization of phospho-Smad2/3 and Snail and cancer cell migration were inhibited by pretreatment with an ERK1/2 inhibitor, PD98059 and a phospho-Smad2 inhibitor, SB203580. Knockdown of Smad2/3 expression suppressed EGF-induced expressions of Snail, vimentin, fibronectin, and cancer cell invasion, suggesting an acquisition of the mesenchymal and migratory phenotype in less aggressive MCF-7 cells. Moreover, MDA-MB-231 cells were shown that EGF-induced EMT, and cell invasion through ERK1/2-phospho-Smad2/3-Snail signaling pathway. We have discovered that EGF-stimulated activation of Smad2/3 upregulated several key EMT markers, inhibited E-cadherin expression, promoted EMT, enhanced migration and invasion in MCF-7 and MDA-MB-231 breast cancer cells. Identification of this molecular mechanism may provide new molecular targets for the development of therapies for metastatic breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.